The development of assays for plasma antiepileptic drug concentrations has led to the discovery of many pharmacokinetic interactions, some causing drug intoxication and others resulting in ineffective drug concentrations. In the 1970s, a number of epileptologists began to argue that single drug therapy was desirable in the treatment of epilepsy and this has become the accepted policy when initiating therapy. About 75% of patients treated in this way will achieve remission with a minimum of adverse drug reactions. The remainder, however, continue to have unacceptable seizures and usually receive combinations of drugs. Evidence indicates that the response rate on adding a second drug is low, although in some studies of new drugs such asvigabatrin up to one-half of patients receiving add-on therapy experience a 50% or greater reduction in seizure frequency, and 10-15% are seizure-free in the short term. Unfortunately, randomized placebo-controlled studies have not been undertaken to compare the relative merits of monotherapy and combination therapy with respect of seizure control and adverse effects. It is argued that the time has come to do so, particularly in view of the known mode of action of some of the new drugs. Perhaps blocking excitation with one drug at the same time as enhancing inhibition with another may be better than doing only one or the other.
INTRODUCTION
It used to be thought that low doses of two drugs in combination gave a greater therapeutic effect with less risk of toxicity than a larger dose of a single drug for the treatment of epilepsy. Now, however, the argument has swung the other way towards monotherapy, and it is felt that a full dose of one drug achieves better control of seizures with fewer adverse effects. The truth probably lies somewhere in between: one drug is adequate for the majority of patients, but a small proportion may require the benefits of rational combination therapy. This paper reviews the evidence which has led to current thinking and considers the debate between monotherapy and combination therapy. It also highlights the need for more scientific evaluation into the effects of combining antiepileptic drugs, so that combination therapy in epilepsy becomes a rational and logical exercise, instead of a random one, as is largely the case at present.
THE BASIS OF THE MONOTHERAPY ARGUMENT
The prevailing opinion among epileptologists nowadays is that single drug therapy for all patients is the desirable goal in the treatment of epilepsy. This view can be traced to several influential studies published in the late 1970s and early 1980s which evaluated the effects of adding a second drug to a patient's seizurecontrol regimen. A retrospective study of 50 patients by Shorvon and Reynolds in 19771 found that the addition of a second drug improved seizure control in only 18 patients (36%). It was concluded by the authors of this study that polypharmacy may, in many cases, be unnecessary. In 1979 the same authors carried out an open, prospective study of 40 patients (without a control group), to examine the effects of reducing combination therapy to monotherapy 2. They concluded that monotherapy was not possible in 11 patients (27%). Of the 29 patients who were reduced to monotherapy treatment, 16 were judged to have become improved, eight remained unchanged and five patients were judged to have become worse clinically. This provided further evidence that only a proportion of patients seemed to benefit from a combination of antiepileptic drugs.
In 1981 Reynolds and Shorvon 3 identified four problems associated with polytherapy: (1) the possibility of long-term toxicity from the drug combination, (2) drug interactions, (3) the failure to evaluate individual drugs in individual patients if one moves too swiftly towards combination therapy, and finally (4) the exacerbation of seizures, which the authors witnessed in some of their patients and which has been reported by many others. In 1982 Schmidt 4 contributed to the growing evidence against polytherapy with a study of 30 patients who had complex partial seizures. A second drug was added to the existing treatment regimen and found that a reduction in seizure frequency of >75% was seen in only 13% of patients. In three patients the seizure frequency was increased by >100%. This may have been either a response to the addition of the second drug or a random occurrence, as seizure frequency does fluctuate. The same author then carried out a study similar to that performed by Reynolds and Shorvon 5, in a prospective trial of 36 patients. Seizure control improved in 13 patients (36%), remained unchanged in 17 patients (47%) and deteriorated in six patients (17%). The results of these studies led to the feeling among epileptologists that monotherapy was the way to treat epilepsy.
THE DEBATE: MONOTHERAPY VS RATIONAL COMBINATION THERAPY
The case for monotherapy has never been proven by a controlled, randomized trial. Neither has the case for combination therapy. No study has been carried out to compare the effects of two drugs in combination vs. one drug alone.
The question, therefore, is whether monotherapy or rational combination therapy, i.e. targeting drugs in a logical way to achieve an optimum effect rather than mixing them up in a random fashion, should be used as standard treatment. Rational combination therapy is not new. It is the norm in many other areas of therapeutics such as Parkinsonism, hypertension, asthma and antibiotic therapy. It is common even in epilepsy therapy. Many practitioners know that while they may aim for monotherapy, around 50% of their patients will be on two drugs or more. Furthermore, many old drugs have multiple sites of action, and are in fact 'combination therapy' in one drug.
The three new drugs currently on the market--vigabatrin, gabapentin and lamotrigine--have all been assessed in classical 'addon' trials, and have therefore all been licensed for 'add-on' therapy. Until monotherapy trials are performed on these drugs we cannot recommend their use for monotherapy. These trials are now under way, but results will not be available for a few more years.
DRUG ACTION AS A BASIS FOR RATIONAL COMBINATION THERAPY
To be able to develop a rational system for combining drugs it is important to know as much as possible about the efficacy of each drug in different seizure types. The mechanisms of action of antiepileptic drugs do not generally give much guidance as to their therapeutic efficacy. The only correlation between pharmacological action of drugs as studied in animals and clinical efficacy in patients is that drugs which act on fast sodium channels appear to be effective in tonic-clonic and partial seizures. Ethosuximide has a specific effect on calcium channels and is useful in absence seizures. But the correlation breaks down in the case of valproate, which is also useful in absence seizures and does not work through calcium channels. It is therefore difficult to extrapolate from experimental data. Data from clinical evidence in published reports are more reliable. Our experience has been that sodium valproate has a wide spectrum of activity, while drugs like carbamazepine and phenytoin are more limited in the range of their action, particularly in myoclonus and absence seizures. Valproate, due to its broad spectrum, is therefore my drug of choice for a wide range of seizures, particularly for practitioners who are less familiar with the treatment of epilepsy.
WHERE DO THE NEW DRUGS FIT IN?
Targeting the tried and tested drugs accurately still poses a challenge, and therefore it is an even more difficult task when we consider the newer agents. Data published so far suggest that lamotrigine has a broad spectrum of activity, although it is less useful in myoclonus.
There is growing evidence for the efficacy of felbamate, not only in refractory partial seizures but also in Lennox-Gastaut syndrome and primary generalized seizures, so the indications for felbamate may extend in the future.
THE NEED FOR GREATER EVALUATION OF EFFECTIVE COMBINATIONS
The creed for monotherapy has held back objective evaluation of drug combinations and the time has come for a reappraisal of the situation. A combination of drugs may have a beneficial effect through pharmacokinetic or pharmacodynamic interaction. A good example of the former is the combination of valproate and lamotrigine, where valproate inhibits lamotrigine metabolism. Less is understood about pharmacodynamic interactions, in which drugs affect receptor sites in a complementary fashion and have additive, or even superadditive effects. Ideally this is what we are looking for--an enhanced effect on combining two drugs, or even potentiation in which we would get greater than twice the effect of each drug on its own. However, this is probably an optimistic target and a modest improvement, in effect, on combining two drugs would still be clinically important.
Increasing knowledge about the way antiepileptic drugs affects the glutamate, and ~-aminobutyric acid (GABA) neurotransmitters has led to the idea that these two mechanisms of action may be combined. For instance, vigabatrin works on GABA transaminase and increases GABA concentration. Tiagabine is another drug which also has a similar effect, as it inhibits the re-uptake of GABA into glial cells and neurones, thus increasing the concentration of GABA at the synapse. Lamotrigine, conversely, acts on the excitatory system on fast sodium channels, inhibiting the release of glutamate. Remacemide is thought to act as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, again reducing excitation. Felbamate probably acts partly on this glycine receptor and the belief is that it reduces excitation.
The question we need to ask ourselves is: should we therefore combine felbamate with vigabatrin, or felbamate with tiagabine? Are there logical combinations which we can now develop? In published but uncontrolled work, 213 vigabatrin and lamotrigine have been claimed to be a good combination 6-s. These reports note a very good potentiating effect between these two drugs. Lamotrigine and valproate are also said to be a good combination--there is the pharmacokinetic mechanism but Pisani 9 and Panayiotopoulos I° claim there is a pharmacodynamic interaction as well, particularly in primary generalized seizures and idiopathic epilepsies.
Controlled clinical trials need to be designed to evaluate these claims in a scientific way. Figure I group design to evaluate the effect of combination therapy properly. Is Dummy A + Dummy B better or worse than either drug given alone? Is lamotrigine and vigabatrin combined better than either drug alone, from the outset?
The second issue to be considered is the management of patients who fail on either drug alone. Are they better off on the two drugs combined? These questions need proper evaluation in a scientific setting before this debate between monotherapy and rational combination therapy can be solved.
